BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Conditions
Advanced Malignancies · Ovarian Cancer · T-cell Lymphoma · Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope National Medical Center, Duarte, California, United States
Contact: Principal Investigator (Christiane Querfeld)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Jasmine Zain)University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Stefan Barta)Rigshospitalet, Copenhagen, Denmark
Contact: Principal Investigator (Kristoffer Staal Rohrberg)Herlev Hospital, Herlev, Denmark
Contact: Principal Investigator (Rikke Løvendahl Eefsen)PRA Health Sciences - Hungary, Budapest, Hungary
Magyar Honvédség-Egészségügyi Központ, Budapest, Hungary
Contact: Principal Investigator (Zsuzsanna Pápai)Debreceni Egyetem Klinikai Központ, Debrecen, Hungary
Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser, Omsk, Russia
National Medical Research Center VA Almazov, Saint Petersburg, Russia
N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
Institut Catala d'oncologia. Hospital Duran I Reynals, Barcelona, Spain
Hospital General Universitario Gregorio Marañon, Madrid, Spain
START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Sahlgrenska University Hospital, Gothenburg, Sweden
Contact: Principal Investigator (Edvard Abel)Skanes University Hospital, Lund, Sweden
Contact: Principal Investigator (Ana Carnerio)Karolinska University Hospital, Solna, Stockholm, Sweden
Contact: Principal Investigator (Jeffrey Yachnin)University Hospital Birmingham, Birmingham, United Kingdom
Contact: Study coordinator (Julia Scarisbrick, Prof.)University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
Contact: Principal Investigator (Harriet Walter)Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Stephen Morris)Sarah Cannon Research Institute UK, London, United Kingdom
Contact: Principal Investigator (Anja Williams)The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Juanita Lopez)The Christie NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Richard Cowan)Southampton General Hospital, Southampton, United Kingdom
Contact: Principal Investigator (Sean Lim)
Study leads
Andres McAllister, PhD
Study Director
BioInvent International AB